Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KOC1 + TTK + CO16 + DEPDC1 + MPHOSPH1
- Development stage
- Phase 1
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Peptides
- Administration
- Subcutaneous, Intradermal
01
Overview
This is a therapeutic cancer vaccine composed of five synthetic peptides derived from tumor-associated antigens: KOC1 (KH domain containing protein overexpressed in cancer 1), TTK (dual specificity protein kinase), CO16 (cancer/testis antigen), DEPDC1 (DEP domain containing 1), and MPHOSPH1 (M-phase phosphoprotein 1). These peptides are designed to induce cytotoxic T lymphocyte responses against tumors expressing these antigens. The combination has been evaluated as an epitope peptide cocktail for use in patients with progressive or relapsed solid tumors—including cervical carcinoma and malignant melanoma—often in combination with immune-modulating agents such as cyclophosphamide or sargramostim. The primary mechanism is the activation of antigen-specific cellular immunity targeting multiple tumor-associated antigens to enhance anti-tumor immune responses[1][3][9].
- Other names
- five peptide vaccine (KOC1, TTK, CO16, DEPDC1, MPHOSPH1)multi-peptide cancer vaccine (KOC1, TTK, CO16, DEPDC1, MPHOSPH1)
02
Targets
LY6K (Lymphocyte antigen 6 complex locus protein K)DEPDC1 (DEP domain-containing protein 1)LCAA (Lung Cancer-Associated Antigen L523S)MPHOSPH1 (M-phase phosphoprotein 1)TTK (TTK protein kinase)ANKHD1 (Ankyrin repeat and KH domain-containing protein 1)
Beyond the preview
Go deeper on KOC1 + TTK + CO16 + DEPDC1 + MPHOSPH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KOC1 + TTK + CO16 + DEPDC1 + MPHOSPH1.